57
Participants
Start Date
December 13, 2022
Primary Completion Date
June 1, 2026
Study Completion Date
June 1, 2026
HMB-001
HMB-001 is a bispecific antibody being developed as a prophylactic treatment option to prevent and reduce bleeding events in patients with Glanzmann thrombasthenia.
Hemophilia Center of Western Pennsylvania (HCWP) (Part B/C), Pittsburgh
Mayo Clinic - Rochester (Part B/C), Rochester
Tulane University Medical Center (Part B/C), New Orleans
University of California, San Diego (UCSD) (Part B/C), La Jolla
Washington Institute for Coagulation (Part B/C), Seattle
University Hospital Leuven - Campus Gasthuisberg (Part B/C), Leuven
AP-HP Hopital Bicetre (Part B/C), Le Kremlin-Bicêtre
AP-HM - Hopital de la Timone, Marseille
AP-HP Hopital Necker-Enfants Malades (Part B/C), Paris
Azienda Ospedaliero-Universitaria Careggi (Part B/C), Florence
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano (Part B/C), Milan
Universitair Medisch Centrum Utrecht (Part B/C), Utrecht
Queen Elizabeth Hospital Birmingham (Part B/C), Birmingham
Leeds Teaching Hospitals NHS Trust, Leeds
Richmond Pharmacology Ltd (Part A/B/C), London
Royal Free London NHS Foundation Trust (Part B/C), London
The Royal London Hospital (Part B/C), Whitechapel
Hemab ApS
INDUSTRY